Dr. Syed Sameer Nasir, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 22
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 1,192
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TN license 55735 · MS license 24958 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Wellspan York Hospital York, PA
- University of Maryland Medical Center Baltimore, MD
- Greater Baltimore Medical Center Baltimore, MD
- University of MD St Joseph Medical Center Towson, MD
- Magnolia Regional Health Center Corinth, MS
Medical groups
- University of Maryland St Joseph Medical Group LLC (287 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,192
- Services billed
- 332,006
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 63,750 | 57 |
| Injection, pembrolizumab, 1 mg | 33,600 | 31 |
| Injection, nivolumab, 1 mg | 24,620 | 18 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 19,050 | 24 |
| Injection, denosumab, 1 mg | 18,060 | 80 |
| Injection, paclitaxel, 1 mg | 13,916 | 26 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 11,160 | 12 |
| Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 7,890 | 22 |
| Injection, dexamethasone sodium phosphate, 1 mg | 6,460 | 109 |
| Injection, docetaxel, 1 mg | 4,765 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 4 payments worth $92.08 in total to this clinician.
| Merck Sharp & Dohme LLC | $53.57 |
|---|---|
| Gilead Sciences, Inc. | $23.94 |
| Jazz Pharmaceuticals Inc. | $14.57 |
| Food and Beverage | $66.38 |
|---|---|
| Education | $25.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Dec 2, 2025 | Education KEYTRUDA · ONCOLOGY · in-kind | $25.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.